Copper Cu 64 Anti-Cea Monoclonal Antibody M5A
Rectal Carcinoma
Explore 111 assets in Rectal Carcinoma →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
monoclonal_antibody
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05245786CT.gov An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Copper Cu 64 Anti-Cea Monoclonal Antibody M5A (this asset) | City of Hope Medical Center | Early P1 | C · 39 |
| Capecitabine | Gustave Roussy, Cancer Campus, Grand Paris | P4 | BBB |
| Floxuridine | City of Hope Medical Center | P2 | BBB |
| Oxaliplatin | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BBB |
| Fluorouracilum | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BBB |
| Irinotecan | SCRI Development Innovations, LLC | P3 | BB |
| Cetuximab | Tang-Du Hospital | P2 | BB |
| Panitumumab | Grupo Espanol Multidisciplinario del Cancer Digestivo | P2 | BB |
| Udenafil | Kyungpook National University Hospital | P4 | BB |
+42 more in the Rectal Carcinoma cohort
Other indications for Copper Cu 64 Anti-Cea Monoclonal Antibody M5A
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | Early P1 | C · 39 |
| Extrahepatic Bile Duct Carcinoma | — | N/A | D · 30 |
| Gallbladder Cancer | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Copper Cu 64 Anti-Cea Monoclonal Antibody M5A in Rectal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/copper-cu-64-anti-cea-monoclonal-antibody-m5a-rectal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →